

References

This is the reference list to the ACE Clinical Guidance "Hypertension – tailoring the management plan to optimise blood pressure control".

1. World Health Organisation (WHO). Hypertension. Available from: <https://www.who.int/news-room/fact-sheets/detail/hypertension> [Accessed 21 November 2023]
2. National Population Health Survey 2022, Epidemiology & Disease Control Division, Ministry of Health and Health Promotion Board, Singapore [Accessed 21 November 2023]
3. van der Weijden T, Bos LB, Koelewijn-van Loon MS. Primary care patients' recognition of their own risk for cardiovascular disease: implications for risk communication in practice. *Curr Opin Cardiol* 2008;23(5):471-476.
4. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. *N Engl J Med*. 2001;345:1291-1297.
5. Chen X, Barywani SB, Hansson PO, et al. High-normal blood pressure conferred higher risk of cardiovascular disease in a random population sample of 50-year-old men: A 21-year follow-up. *Medicine (Baltimore)*. 2020 Apr;99(17):e19895.
6. Márquez DF, Rodríguez-Sánchez E, de la Morena JS, et al. Hypertension mediated kidney and cardiovascular damage and risk stratification: Redefining concepts. *Nefrologia (Engl Ed)* 2022;42(5):519-530.
7. Oh JS, Lee CH, Park JL, et al. Hypertension-mediated organ damage and long-term cardiovascular outcomes in Asian hypertensive patients without prior cardiovascular disease. *J Korean Med Sci*. 2020;35(48):e400.
8. Vasan RS, Song RJ, Xanthakis V, et al. Hypertension-mediated organ damage: prevalence, correlates, and prognosis in the community. *Hypertension*. 2022;79(3):505-515.
9. Puar TH, Mok Y, Debajyoti R, et al. Secondary hypertension in adults. *Singapore Med J*. 2016;57(5):228-232.
10. Health Promotion Board (HPB). Alcohol — more than meets the eye. Available from: <https://www.healthhub.sg/live-healthy/alcohol-%20hazards%20and%20benefits> [Accessed 1 December 2023]
11. Loh KC, Koay ES, Khaw MC, et al. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. *J Clin Endocrinol Metab*. 2000;85(8):2854-2859.
12. Canoy D, Copland E, Nazarzadeh M, et al. Antihypertensive drug effects on long-term blood pressure: an individual-level data meta-analysis of randomised clinical trials. *Heart*. 2022;108:1281-1289.
13. Blood Pressure Lowering Treatment Trialists' Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. *Lancet*. 2021;397(10285):1625-1636.
14. Brunström M, Carlberg B. Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis. *JAMA Intern Med*. 2018;178(1):28-36.
15. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials. *J Hypertens*. 2017;35(11):2150-2160.
16. Blumenthal JA, Babyak MA, Hinderliter A, et al. Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE study. *Arch Intern Med*. 2010;170(2):126–135.
17. Appel LJ, Champagne CM, Harsha DW, et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. *JAMA*. 2003;289(16):2083-2093.
18. Krishnamoorthy Y, Nagarajan R, Murali S, et al. Effectiveness of multiple combined lifestyle interventions in reducing blood pressure among patients with prehypertension and hypertension: a network meta-analysis. *J Public Health (Oxf)*. 2023;45(2):e319-e331.
19. Bahat G, Ozkok S, Petrovic M. Treating hypertension in older adults in light of the recent STEP trial: Can we implement the findings in geriatric practice? *Drugs Aging*. 2022;39(12):915-921.

20. Guasti L, Ambrosetti M, Ferrari M, et al. Management of hypertension in the elderly and frail patient. *Drugs Aging*. 2022;39(10):763-772.
21. Lonn EM, Bosch J, López-Jaramillo P, et al. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. *N Engl J Med*. 2016;374(21):2009-2020.
22. Law M, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. *BMJ*. 2009;338(b1665).
23. Materson B, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. *N Engl J Med*. 1993;328(13):914-921.
24. Neaton J, Grimm RH Jr, Prineas RJ, et al. Treatment of mild hypertension study: final results. *JAMA*. 1993;270(6):713-724.
25. Turnbull F, Neal B, Ninomiya T, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. *BMJ*. 2008;336(7653):1121-1123.
26. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. *Lancet*. 2016;387(10022):957-967.
27. Nochaiwong S, Chuamanochan M, Ruengorn C, et al. Use of thiazide diuretics and risk of all types of skin cancers: an updated systematic review and meta-analysis. *Cancers (Basel)* 2022;14(10):2566.
28. Shao S, Lai CC, Chen YH, et al. Associations of thiazide use with skin cancers: a systematic review and meta-analysis. *BMC Med*. 2022;20:228-242.
29. Health Sciences Authority (HSA). Update on the recent study findings on the risk of non-melanoma skin cancer with prolonged use of hydrochlorothiazide. Available from <https://www.hsa.gov.sg/announcements/safety-alert/update-on-the-recent-study-findings-on-the-risk-of-non-melanoma-skin-cancer-with-prolonged-use-of-hydrochlorothiazide> [Accessed 21 November 2023]
30. Hashizume H, Nakatani E, Sasaki H, et al. Hydrochlorothiazide increases risk of nonmelanoma skin cancer in an elderly Japanese cohort with hypertension: the Shizuoka study. *JAAD Int*. 2023;12:49-57.
31. Thomopoulos C, Bazoukis G, Tsioufis C, et al. Beta-blockers in hypertension: overview and meta-analysis of randomized outcome trials. *J Hypertens*. 2020;38:1669-1681.
32. Wiysonge C, Bradley HA, Volmink J, et al. Beta-blockers for hypertension. *Cochrane Database Syst Rev*. 2017(1):CD002003. doi: 10.1002/14651858.CD002003.pub2.
33. You S, Krumholz HM, Suchard MA, et al. Comprehensive comparative effectiveness and safety of first-line beta-blocker monotherapy in hypertensive patients – a large-scale multicenter observational study. *Hypertension*. 2021;77:1528–1538.
34. Seleme V, Marques GL, Mendes AEM, et al. Nebivolol for the treatment of essential systemic arterial hypertension: a systematic review and meta-analysis. *Am J Cardiovasc Drugs*. 2021;21:165-180.
35. Mancía G, Kjeldsen SE, Kreutz R, et al. Individualized beta-blocker treatment for high blood pressure dictated by medical comorbidities: indications beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines. *Hypertension*. 2022;79(6):1153-1166.
36. Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. *BMJ*. 2003;28(326):1427.
37. Bennett A, Chow CK, Chou M, et al. Efficacy and safety of quarter-dose blood pressure-lowering agents: a systematic review and meta-analysis of randomized controlled trials. *Hypertension*. 2017;70(1):85-93.
38. Paz MA, de-La-Sierra A, Sáez M, et al. Treatment efficacy of anti-hypertensive drugs in monotherapy or combination: ATOM systematic review and meta-analysis of randomized clinical trials according to PRISMA statement. *Medicine (Baltimore)*. 2016;95(30):e4071.
39. Pongpanich P, Pitakpaiboonkul P, Takkavatakarn K, et al. The benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis. *International Urology and Nephrology*. 2018;50:2261-2278.
40. Guerrero-García C, Rubio-Guerra AF. Combination therapy in the treatment of hypertension. *Drugs Context*. 2018 Jun 6;7:212531.

41. Mancia G RF, Corrao G, Grassi G. Two-drug combinations as first-step antihypertensive treatment. *Circ Res.* 2019;124(7):1113-1123.
42. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. *N Engl J Med.* 2008;359(23):2417-2428.
43. Matsuzaki M, Ogihara T, Umemoto S, et al. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. *Journal of Hypertension.* 2011;29(8):1649-1659.
44. Umemoto S, Ogihara T, Matsuzaki M, et al. Effects of an antihypertensive combination in Japanese hypertensive outpatients based on the long-acting calcium channel blocker benidipine on vascular and renal events: A sub-analysis of the COPE trial. *Current Hypertension Reviews.* 2020;16:238-245.
45. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. *Am J Med.* 2007;120(8):713-719.
46. Weisser B, Predel H-G, Gillessen A, et al. Single pill regimen leads to better adherence and clinical outcome in daily practice in patients suffering from hypertension and/or dyslipidemia: results of a meta-analysis. *High Blood Press Cardiovasc Prev.* 2020;27(2):157-164.
47. Wald D, Law M, Morris JK. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. *Am J Med.* 2009;122:290-300.
48. Aubert C, Sussman JB, Hofer TP, et al. Adding a new medication versus maximizing dose to intensify hypertension treatment in older adults: A retrospective observational study. *Ann Intern Med.* 2021. 174(12):1666-1673.
49. Lasserson DS, Thierry B, Glasziou P, et al. How quickly should we titrate antihypertensive medication? Systematic review modelling blood pressure response from trial data. *Heart.* 2011;97(21):1771-1775.
50. Xu W, Goldberg SI, Shubina M, et al. Optimal systolic blood pressure target, time to intensification, and time to follow-up in treatment of hypertension: population based retrospective cohort study. *BMJ.* 2015;350(h158).
51. Maqsood MH, Messerli FH, Skolnick AH, et al. Timing of antihypertensive drug therapy: a systematic review and meta-analysis of randomized clinical trials. *Hypertension.* 2023;80(7):1544-1554.
52. Sheppard J, Tucker KL, Davison WJ, et al. Self-monitoring of blood pressure in patients with hypertension-related multi-morbidity: systematic review and individual patient data meta-analysis. *Am J Hypertens.* 2020 33(3):243-251.
53. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension.* 2018 Jun;71(6):1269-1324.